Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Researchers demonstrate potential neurochemical mechanism of weight loss

An interdisciplinary group of researchers at the University of Pennsylvania has, for the first time, identified the neurological and cellular signaling mechanisms that contribute to satiety - the sensation of feeling full - and the subsequent body-weight loss produced by drugs used to treat type 2 diabetes. More comprehensive knowledge of these mechanisms could form the basis for anti-obesity medications.

4 Mar 2011

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo Pharmaceuticals announced that FORTESTA Gel – recently approved by the U.S. Food and Drug Administration for the treatment of low testosterone, or 'Low T' in adult males – is now available by prescription in pharmacies across the country.

3 Mar 2011

New study: Lower potassium levels may help explain racial disparity in type 2 diabetes

Lower potassium levels in the blood may help explain why African-Americans are twice as likely to be diagnosed with type 2 diabetes as whites, according to a new study by Johns Hopkins researchers.

3 Mar 2011

Study identifies key gene mutation responsible for type 2 diabetes in nearly 10% of patients

A multinational study has identified a key gene mutation responsible for type 2 diabetes in nearly 10 percent of patients of white European ancestry.

2 Mar 2011

Researchers find mineral deficiency increases type 2 diabetes risk in African-Americans

Lower potassium levels in the blood may help explain why African-Americans are twice as likely to be diagnosed with type 2 diabetes as whites, according to a new study by Johns Hopkins researchers.

2 Mar 2011

Scientists discover how change in growth hormone activity leads to fatty liver disease

Scientists at the UCSF Cardiovascular Research Institute have discovered how a change in growth hormone activity in mice leads to fatty liver disease, a condition whose human counterpart is of rising concern worldwide.

2 Mar 2011

Regular exercise cuts risk of bowel cancer

People with an active lifestyle are up to three times less likely to develop large or advanced polyps in the bowel - which can develop into bowel cancer - according to a new analysis published in the British Journal of Cancer today (Wednesday).

1 Mar 2011

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device for use with NovoLog

Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S. Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.

1 Mar 2011

Researchers discover new mechanism of beta cell destruction not previously known

The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.

28 Feb 2011

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Researchers at the University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego say an evolutionary gene mutation that occurred in human millions of years ago and our subsequent inability to produce a specific kind of sugar molecule appears to make people more vulnerable to developing type 2 diabetes, especially if they're overweight.

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

As if the recent prediction that half of all Americans will have diabetes or pre-diabetes by the year 2020 isn't alarming enough, a new genetic discovery published online in the FASEB Journal provides a disturbing explanation as to why: we took an evolutionary "wrong turn."

25 Feb 2011

Study: Individuals with fatty liver more likely to develop type 2 diabetes

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that individuals with fatty liver were five times more likely to develop type 2 diabetes than those without fatty liver. This higher risk seemed to occur regardless of the patient's fasting insulin levels, which were used as a marker of insulin resistance.

24 Feb 2011

Simple home urine test can measure insulin in patients with diabetes

A simple home urine test has been developed which can measure if patients with Type 1 and Type 2 diabetes are producing their own insulin. The urine test, from Professor Andrew Hattersley's Exeter-based team at the Peninsula Medical School, replaces multiple blood tests in hospital and can be sent by post as it is stable for up to three days at room temperature.

24 Feb 2011

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.

24 Feb 2011

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.

24 Feb 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

ACT receives patent for its single-blastomere technology

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique. Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell lines.

23 Feb 2011

Diabetes technology granted patent in Australia

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL(tm), LCT's industry-leading technology for encapsulating living cells prior to transplantation.

23 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Insulin News and Research

Further Reading

Researchers demonstrate potential neurochemical mechanism of weight loss

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

New study: Lower potassium levels may help explain racial disparity in type 2 diabetes

Study identifies key gene mutation responsible for type 2 diabetes in nearly 10% of patients

Researchers find mineral deficiency increases type 2 diabetes risk in African-Americans

Scientists discover how change in growth hormone activity leads to fatty liver disease

Regular exercise cuts risk of bowel cancer

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device for use with NovoLog

Researchers discover new mechanism of beta cell destruction not previously known

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Research sheds new light on problem of insulin resistance in type 2 diabetes

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

Study: Individuals with fatty liver more likely to develop type 2 diabetes

Simple home urine test can measure insulin in patients with diabetes

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

ACT receives patent for its single-blastomere technology

Diabetes technology granted patent in Australia

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News